Navigation Links
Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer

Study Fails to Meet Primary Endpoint of Improvement in Overall Survival

WESTMINSTER, Colo., June 19, 2007 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. today announced top line results from ENRICH, the Company's pivotal Phase 3 study of Efaproxyn (efaproxiral) plus whole brain radiation therapy (WBRT) in women with brain metastases originating from breast cancer. The study failed to achieve its primary endpoint of demonstrating a statistically significant improvement in overall survival in patients receiving Efaproxyn plus WBRT, compared to patients receiving WBRT alone. Based on these results, the Company intends to discontinue the development of Efaproxyn and focus on advancing the development of PDX (pralatrexate), its novel antifolate currently under evaluation in a pivotal Phase 2 study in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

"I would like to acknowledge the patients and investigators for their participation in the ENRICH study," said Paul L. Berns, President and Chief Executive Officer of Allos. "We continue to move forward with focus and determination in advancing the clinical development of PDX and RH1, and look forward to providing future updates on our clinical progress."

Results of the ENRICH study indicated that patients who received EFAPROXYN plus WBRT did not experience a statistically significant improvement in survival compared to patients who received WBRT alone, according to a stratified log rank analysis of overall survival (8.5 months vs. 7.5 months; hazard ratio 0.87, p-value = 0.23). All secondary efficacy endpoints also failed to achieve statistical significance. The study safety results demonstrated that EFAPROXYN was generally well tolerated. The most common Grade 3-4 adverse events that occurred more often in the EFAPROXYN arm included headache, hypoxia and vomiting. Adverse events in the study appeared to be similar to those obser
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:9/19/2014)... HILL, N.C. , Sept. 19, 2014 ... to Best Practices, LLC with three issues he wanted ... , The use of external personnel (especially for secondary ... headcount in the face of increased workload , ... and better knowledge management , How to implement ...
(Date:9/19/2014)... , Sept. 19, 2014 ... used to inflate sales of brand drugs among ... D,  according to a new report  from ... Office of the Inspector General (OIG). Federal anti-kickback laws ... of goods that are subsidized by the federal ...
(Date:9/19/2014)... Sept. 19, 2014 /PRNewswire-iReach/ -- Market Research ... Industry, 2009-2019 is a professional and in-depth ... Hydrochloride industry. The report firstly reviews the ... classification, application and manufacturing technology. The report ... of Oxybutynin Hydrochloride listing their product specification, ...
Breaking Medicine Technology:In Era of Competing Needs, Market Research Groups Under Pressure to Utilize Automation and External Staffing 2PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5
(Date:9/22/2014)... 2014--Women who are about to be released from prison ... if they are to successfully reintegrate into their communities ... study. , Almost half of all female prisoners are ... and most have multiple prison terms, mainly for drug-related ... Michael,s Hospital, conducted one-on-one interviews with women who were ...
(Date:9/22/2014)... September 22, 2014 BCC Research ... AUTOIMMUNE DISEASE DIAGNOSTICS: GLOBAL MARKETS, the global ... grow to nearly $13.1 billion by 2019, with ... 1.6%. Southern Asia holds the highest market ... factors and adoption of western lifestyles. , ...
(Date:9/22/2014)... the American College of Surgeons, Committee on Trauma, patients ... or level II trauma centers. Those centers have the ... , But 1 out of 3 major trauma patients ... centers or nontrauma centers, according to a new study ... Center for Injury Research and Policy at Nationwide Children,s ...
(Date:9/22/2014)... study by the Cancer Science Institute of Singapore ... (NUS) found that an increase in a gene ... directly implicated in acute myelogenous leukaemia (AML), increasing ... Associate Professor Chng Wee Joo, Deputy Director and ... of the National University Cancer Institute, Singapore, the ...
(Date:9/22/2014)... “I don’t belong there. My mind is fine. I ... of "My Inner Child Must Be Heard: From Despair to ... her six-decade battle with polio and subsequent struggles with clinical ... limitation is a way of life for Zalace. With over ... car accident in her history, she credits her positive outlook ...
Breaking Medicine News(10 mins):Health News:Involving female offenders in release planning can increase reintegration success 2Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 2Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 3Health News:New study finds 34 percent of severely injured patients undertriaged in the United States 2Health News:New study finds 34 percent of severely injured patients undertriaged in the United States 3Health News:Singapore researchers discover a gene that increases incidence of AML 2Health News:Polio Survivor Chronicles Journey in New Collection of Poems 2
... study finds , , THURSDAY, Sept. 27 (HealthDay News) -- ... trauma victims suffering from heavy blood loss and shock, ... the first scientific study showing the benefits of using ... Poloujadoff, an emergency physician at one of the University ...
... Mich., Sept. 27 Stryker,Corporation (NYSE: SYK ... resolution,with the United States Attorney,s office in Newark, ... practices in the,orthopaedic industry. The investigation began with ... 2005 that requested documents for the,period January 2002 ...
... ... supplemented, Unveils Campaign to Help Consumers Measure Their ... ... the creators of,the "Life ... supplemented" campaign set out to determine ... the launch of a,new Web site -- http://www.lifesupplemented.org -- ...
... NEWPORT NEWS, Va., Sept. 27 The Patient,Advocate ... patient services to tens of thousands of patients ... care because of financial or insurance,denials --announced this ... including health care policy leaders and medical professionals ...
... develop gene-based screens , , THURSDAY, Sept. 27 (HealthDay News) ... develop genetic tests that predict which patients will have ... a nonprofit organization dubbed the International Serious Adverse Events ... at drug-related liver toxicity and the other aimed at ...
... MANHATTAN, KAN. -- Workshops, online programs and databases are ... shares knowledge about the biosciences, food safety and animal ... of our food supply. , In the past 27 ... States and around the world have turned to Kansas ...
Cached Medicine News:Health News:Toxic Shock Drug Might Aid Trauma Victims 2Health News:Toxic Shock Drug Might Aid Trauma Victims 3Health News:Stryker Announces Resolution Related to March 2005 U.S. Department of Justice Subpoena 2Health News:Are You An AlphaWell or An OhWell? 2Health News:Patient Advocate Foundation Welcomes Leading Health Care Experts to Executive Board of Directors 2Health News:Patient Advocate Foundation Welcomes Leading Health Care Experts to Executive Board of Directors 3Health News:Drug Industry Seeks Tests to Spot Side Effect Risks 2Health News:Drug Industry Seeks Tests to Spot Side Effect Risks 3Health News:Professionals in bioscience, food-related industries turn to K-State 2Health News:Professionals in bioscience, food-related industries turn to K-State 3
... is a family of solutions that ... individuals inside hospitals, healthcare facilities, or ... The target tracking areas are networked ... of radio frequency identification (RFID) readers ...
Assetrac allows identification, location, and protection of your assets....
... The RoamAlert Integrity system builds ... ECO. All door controllers in the ... computer running a standard Windows® operating ... the use of a personal computer, ...
... uses RFID to gather patient ... departments such as surgical and ... updates of patient location to ... care events have occurred and ...
Medicine Products: